CN115956081A - 具有作为alk2抑制剂的活性的咪唑并哒嗪化合物 - Google Patents
具有作为alk2抑制剂的活性的咪唑并哒嗪化合物 Download PDFInfo
- Publication number
- CN115956081A CN115956081A CN202180041015.0A CN202180041015A CN115956081A CN 115956081 A CN115956081 A CN 115956081A CN 202180041015 A CN202180041015 A CN 202180041015A CN 115956081 A CN115956081 A CN 115956081A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- compounds
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Dental Preparations (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038410P | 2020-06-12 | 2020-06-12 | |
| US63/038,410 | 2020-06-12 | ||
| PCT/US2021/036839 WO2021252781A1 (en) | 2020-06-12 | 2021-06-10 | Imidazopyridazine compounds with activity as alk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115956081A true CN115956081A (zh) | 2023-04-11 |
Family
ID=76971994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180041015.0A Pending CN115956081A (zh) | 2020-06-12 | 2021-06-10 | 具有作为alk2抑制剂的活性的咪唑并哒嗪化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11840546B2 (https=) |
| EP (1) | EP4165051A1 (https=) |
| JP (1) | JP2023530088A (https=) |
| KR (1) | KR20230025434A (https=) |
| CN (1) | CN115956081A (https=) |
| AR (1) | AR122587A1 (https=) |
| AU (1) | AU2021288107A1 (https=) |
| BR (1) | BR112022025191A2 (https=) |
| CA (1) | CA3184811A1 (https=) |
| CL (1) | CL2022003453A1 (https=) |
| CO (1) | CO2022017969A2 (https=) |
| EC (1) | ECSP22093652A (https=) |
| IL (1) | IL298248A (https=) |
| MX (1) | MX2022015493A (https=) |
| PE (1) | PE20230491A1 (https=) |
| TW (1) | TWI895442B (https=) |
| WO (1) | WO2021252781A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| ATE522249T1 (de) * | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
| AR068877A1 (es) | 2007-10-17 | 2009-12-09 | Novartis Ag | Derivados heterociclicos de imidazol |
| CA2806655A1 (en) | 2010-07-28 | 2012-02-02 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-b]pyridazines |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| CA2834901A1 (en) | 2011-05-06 | 2012-11-15 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| WO2014160203A2 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20190218214A1 (en) | 2016-09-14 | 2019-07-18 | Vanderbilt University | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof |
| MX2019002951A (es) | 2016-09-15 | 2019-09-11 | Armstrong World Ind Inc | Sistema de techo con movimiento aereo. |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| WO2018136634A1 (en) | 2017-01-18 | 2018-07-26 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| WO2018165569A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods |
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
-
2021
- 2021-06-10 CA CA3184811A patent/CA3184811A1/en active Pending
- 2021-06-10 CN CN202180041015.0A patent/CN115956081A/zh active Pending
- 2021-06-10 MX MX2022015493A patent/MX2022015493A/es unknown
- 2021-06-10 WO PCT/US2021/036839 patent/WO2021252781A1/en not_active Ceased
- 2021-06-10 AR ARP210101581A patent/AR122587A1/es unknown
- 2021-06-10 BR BR112022025191A patent/BR112022025191A2/pt unknown
- 2021-06-10 AU AU2021288107A patent/AU2021288107A1/en not_active Withdrawn
- 2021-06-10 IL IL298248A patent/IL298248A/en unknown
- 2021-06-10 PE PE2022002872A patent/PE20230491A1/es unknown
- 2021-06-10 TW TW110121255A patent/TWI895442B/zh active
- 2021-06-10 EP EP21743321.8A patent/EP4165051A1/en active Pending
- 2021-06-10 JP JP2022576034A patent/JP2023530088A/ja not_active Ceased
- 2021-06-10 KR KR1020237000999A patent/KR20230025434A/ko active Pending
- 2021-06-10 US US17/344,255 patent/US11840546B2/en active Active
-
2022
- 2022-12-06 CL CL2022003453A patent/CL2022003453A1/es unknown
- 2022-12-09 EC ECSENADI202293652A patent/ECSP22093652A/es unknown
- 2022-12-12 CO CONC2022/0017969A patent/CO2022017969A2/es unknown
-
2023
- 2023-10-31 US US18/385,742 patent/US20240083918A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023530088A (ja) | 2023-07-13 |
| WO2021252781A1 (en) | 2021-12-16 |
| CA3184811A1 (en) | 2021-12-16 |
| AR122587A1 (es) | 2022-09-21 |
| IL298248A (en) | 2023-01-01 |
| EP4165051A1 (en) | 2023-04-19 |
| US20240083918A1 (en) | 2024-03-14 |
| KR20230025434A (ko) | 2023-02-21 |
| ECSP22093652A (es) | 2023-02-28 |
| AU2021288107A1 (en) | 2022-12-15 |
| US20210388003A1 (en) | 2021-12-16 |
| CO2022017969A2 (es) | 2023-02-27 |
| US11840546B2 (en) | 2023-12-12 |
| CL2022003453A1 (es) | 2023-05-26 |
| BR112022025191A2 (pt) | 2023-03-07 |
| TW202214660A (zh) | 2022-04-16 |
| TWI895442B (zh) | 2025-09-01 |
| MX2022015493A (es) | 2023-03-21 |
| PE20230491A1 (es) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11591329B2 (en) | Bicyclic heterocycles as FGFR inhibitors | |
| US11492354B2 (en) | Indazole compounds and uses thereof | |
| US11897891B2 (en) | Tricyclic heterocycles as FGFR inhibitors | |
| US11299473B2 (en) | Benzimidazole and indole compounds and uses thereof | |
| US11111247B2 (en) | Pyrazolopyrimidine compounds and uses thereof | |
| JP7723068B2 (ja) | アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物 | |
| US11840546B2 (en) | Imidazopyridazine compounds and uses thereof | |
| EA046773B1 (ru) | Соединения имидазопиридазина, активные в качестве ингибиторов alk2 | |
| EA050836B1 (ru) | Соединения имидазопиридазина и их применения | |
| HK40057772B (en) | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |